Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines.
$38.88+6.17%
报价 2026-11-06
市值
$28.08B
EV
$28.82B
PE (TTM)
–
预期 PE
–
52 周区间距高点 -7.0%
$20.10$41.81
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ROIVRoivant Sciences Ltd. | $28.08B | +6.2% | – | 81.2% | – | – | – | |
| GMABGenmab A/S | $32.98B | +1.7% | – | 39.9% | 45.6x | 28.5x | 41.3x | |
| RPRXRoyalty Pharma plc | $29.97B | -0.4% | +14.8% | 100% | 25.6x | 17.1x | 12.1x | |
| INSMInsmed Incorporated | $25.1B | +5.2% | +191.4% | 84.3% | – | – | – | |
| INCYIncyte Corporation | $24.39B | +1.4% | +12.9% | 91.8% | 13.9x | 8.5x | 17.9x | |
| UTHRUnited Therapeutics Corporation | $24.11B | -0.7% | +1.9% | 86.1% | 17.9x | 12.8x | 21.0x | |
| BNTXBioNTech SE | $21.7B | +1.9% | – | 69% | – | – | 48.8x | |
| ALNYAlnylam Pharmaceuticals, Inc. | $20.89B | -0.5% | +49.7% | 81.7% | 129.2x | 85.2x | 44.7x | |
| EXELExelixis, Inc. | $17.49B | +1.3% | +11.8% | 96.4% | 14.4x | 11.5x | 20.6x | |
| 同行中位数 | – | – | +13.8% | 85.2% | 21.7x | 14.9x | 21.0x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。